These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 23528368

  • 1. Activation of nuclear factor-κB contributes to growth and aggressiveness of papillary thyroid carcinoma.
    Pyo JS, Kang G, Kim DH, Chae SW, Park C, Kim K, Do SI, Lee HJ, Kim JH, Sohn JH.
    Pathol Res Pract; 2013 Apr; 209(4):228-32. PubMed ID: 23528368
    [Abstract] [Full Text] [Related]

  • 2. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S, Go C, Aniss A, Sidhu S, Delbridge L, Learoyd D, Clifton-Bligh R, Tacon L, Tsang V, Robinson B, Gill AJ, Sywak M.
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [Abstract] [Full Text] [Related]

  • 3. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.
    Kim Y, Kim MH, Jeon S, Kim J, Kim C, Bae JS, Jung CK.
    PLoS One; 2017 Jul; 12(3):e0174737. PubMed ID: 28358874
    [Abstract] [Full Text] [Related]

  • 4. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
    Bommarito A, Richiusa P, Carissimi E, Pizzolanti G, Rodolico V, Zito G, Criscimanna A, Di Blasi F, Pitrone M, Zerilli M, Amato MC, Spinelli G, Carina V, Modica G, Latteri MA, Galluzzo A, Giordano C.
    Endocr Relat Cancer; 2011 Dec; 18(6):669-85. PubMed ID: 21903858
    [Abstract] [Full Text] [Related]

  • 5. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAFV600E mutation.
    Lee YK, Park KH, Park SH, Kim KJ, Shin DY, Nam KH, Chung WY, Lee EJ.
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [Abstract] [Full Text] [Related]

  • 6. The prognostic relevance of psammoma bodies and ultrasonographic intratumoral calcifications in papillary thyroid carcinoma.
    Pyo JS, Kang G, Kim DH, Park C, Kim JH, Sohn JH.
    World J Surg; 2013 Oct; 37(10):2330-5. PubMed ID: 23716027
    [Abstract] [Full Text] [Related]

  • 7. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
    Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, Kim JS.
    Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
    [Abstract] [Full Text] [Related]

  • 8. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH, Kim IJ, Lee BJ, Lee JC, Kim IS, Kim SJ, Kim WJ, Jeon YK, Kim SS, Kim YK.
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [Abstract] [Full Text] [Related]

  • 9. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
    Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, Kim JS.
    Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
    [Abstract] [Full Text] [Related]

  • 10. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY, Yoo JH, Park ES, Kim MK, Lee TJ, Cho BY, Chung YJ, Kang KH, Ahn HY, Kim HS.
    Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
    [Abstract] [Full Text] [Related]

  • 11. Follicular variant of papillary thyroid carcinoma with B-type Raf(V600E) showing higher frequency of suspicious sonographic features and multifocality.
    Shin DY, Kim KJ, Chang S, Kim H, Hwang S, Kim W, Bae J, Park S, Kang SW, Chung WY, Lee EJ.
    Head Neck; 2015 Nov; 37(11):1590-5. PubMed ID: 24909403
    [Abstract] [Full Text] [Related]

  • 12. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
    Shi CL, Guo Y, Lyu YC, Nanding ZABYS, Gao WC, Shi TF, Qin HD, Liu SY.
    Zhonghua Zhong Liu Za Zhi; 2017 May 23; 39(5):361-366. PubMed ID: 28535653
    [Abstract] [Full Text] [Related]

  • 13. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J, Drabek J, Dudesek B, Vazan P, Stranska J, Jancik S, Mackova M, Syrucek M, Lukas D, Duskova J, Dundr P, Hintnausova B, Jiskra J.
    Exp Clin Endocrinol Diabetes; 2014 May 23; 122(5):268-72. PubMed ID: 24839220
    [Abstract] [Full Text] [Related]

  • 14. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases.
    Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, Ren X, Gao M.
    Ann Surg Oncol; 2013 Jul 23; 20(7):2266-73. PubMed ID: 23370668
    [Abstract] [Full Text] [Related]

  • 15. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
    Sun J, Zhang J, Lu J, Gao J, Lu T, Ren X, Duan H, Liang Z.
    Int J Clin Exp Pathol; 2015 Jul 23; 8(11):15072-8. PubMed ID: 26823846
    [Abstract] [Full Text] [Related]

  • 16. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
    Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA.
    JAMA Otolaryngol Head Neck Surg; 2013 Nov 23; 139(11):1164-70. PubMed ID: 24030686
    [Abstract] [Full Text] [Related]

  • 17. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
    Yip L, Nikiforova MN, Yoo JY, McCoy KL, Stang MT, Armstrong MJ, Nicholson KJ, Ohori NP, Coyne C, Hodak SP, Ferris RL, LeBeau SO, Nikiforov YE, Carty SE.
    Ann Surg; 2015 Sep 23; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
    [Abstract] [Full Text] [Related]

  • 18. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK, Chong A, Ha JM, Jung CK, O JH, Kim SH.
    Clin Endocrinol (Oxf); 2017 Jul 23; 87(1):73-79. PubMed ID: 28329426
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.